Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to discontinue development of the drug. Separately, a surprise FDA inspection is underway at Sun Pharma’s Halol manufacturing facility.
Rate cuts unlikely in near term as inflation stays sticky: Richard Harris
Global market expert Richard Harris anticipates minimal changes to U.S. monetary policy, emphasizing the Fed’s independence. He notes that Big Tech’s recent profitability stems more